on Wednesday flagged promising late-stage demo results for its new Cagrilinitide being overweight therapy, because the Danish pharmaceutical big seeks a next-technology choice to its blockbuster Wegovy excess weight-loss drug.Cagrilintide is actively getting examined for its likely to advertise weight loss in persons without sort 2 diabetic issues